Indication
Clear Cell Carcinoma
5 clinical trials
8 products
4 drugs
Clinical trial
A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate CancerStatus: Recruiting, Estimated PCD: 2025-03-15
Product
vudalimabClinical trial
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV07/ ENGOT-ov80 Study)Status: Not yet recruiting, Estimated PCD: 2027-08-31
Product
DostarlimabDrug
AtezolizumabDrug
R-CHOPDrug
GemcitabineDrug
TiragolumabClinical trial
Phase II Trial of Single-Agent Nivolumab in Patients With Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine CancerStatus: Completed, Estimated PCD: 2024-04-01
Product
NivolumabClinical trial
Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer PatientsStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Product
RucaparibProduct
PlacebosClinical trial
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy (N-Plus)Status: Not yet recruiting, Estimated PCD: 2027-05-01
Product
3 cycles chemotherapyProduct
6 cycles chemotherapy